Page 1215 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

2 References

30. Waterhouse EJ, Vaughan JK, Barnes TY, et al. Synergistic effect patients undergoing cardiac surgery who received tranexamic
of status epilepticus and ischemic brain injury on mortality. acid: a case-control study. Ann Card Anaesth. 2012;15:6-12.
Epilepsy Res. 1998;29:175-183. 54. Klein C, Balash Y, Pollak L, Hiss J, Rabey MJ. Body packer: cocaine
31. Aminoff MJ, Simon RP. Status epilepticus. Causes, clinical intoxication, causing death, masked by concomitant administra-
features and consequences in 98 patients. Am J Med. 1980;69: tion of major tranquilizers. Eur J Neurol. 2000;7:555-558.
657-666. 55. So YT. Effects of drug abuse on the nervous system. In: Bradley
32. Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of WG, Daroff RB, Fenichel GM, Marsden CD, ed. Neurology in
mortality in status epilepticus. Epilepsia. 1994;35:27-34. Clinical Practice. 3rd ed. Boston, MA: Butterworth Heinemann;
33. Kravljanac R, Jovic N, Djuric M, Jankovic B, Pekmezovic T. 2000:1521.
Outcome of status epilepticus in children treated in the inten- 56. Balit CR, Lynch CN, Isbister GK. Bupropion poisoning: a case
sive care unit: a study of 302 cases. Epilepsia. 2011;52:358-363. series. Med J Aust. 2003;178:61-63.
34. Kaplan PW. Nonconvulsive status epilepticus in the emergency 57. Hennis A, Corbin D, Fraser H. Focal seizures and non-ketotic
room. Epilepsia. 1996;37:643-650. hyperglycaemia. J Neurol Neurosurg Psychiatry. 1992;55:195-197.
35. Van Cott AC, Blatt I, Brenner RP. Stimulus-sensitive seizures in 58. Morres CA, Dire DJ. Movement disorders as a manifestation of
postanoxic coma. Epilepsia. 1996;37:868-874. nonketotic hyperglycemia. J Emerg Med. 1989;7:359-364.
36. www.epilepsy.org. (Accessed February, 15, 2012) 59. Tiamkao S, Pratipanawatr T, Nitinavakarn B, Chotmongkol V,
37. Fountain NB, Lothman EW. Pathophysiology of status epilepti- Jitpimolmard S. Seizures in nonketotic hyperglycaemia. Seizure.
cus. J Clin Neurophysiol. 1995;12:326-342. 2003;12:409-410.
38. Simon RP, Aminoff MJ, Benowitz NL. Changes in plasma catechol- 60. Bleck TP. Less common etiologies of status epilepticus. Epilepsy
amines after tonic-clonic seizures. Neurology. 1984;34:255-257. Curr. 2010;10:31-33.
39. Boggs JG, Painter JA, DeLorenzo RJ. Analysis of electrocardio- 61. Lee R, Buckley C, Irani SR, Vincent A. Autoantibody testing in
graphic changes in status epilepticus. Epilepsy Res. 1993;14:87-94. encephalopathies. Pract Neurol. 2012;12:4-13.
40. Boggs JG, Marmarou A, Agnew JP, et al. Hemodynamic moni- 62. DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent
toring prior to and at the time of death in status epilepticus. nonconvulsive status epilepticus after the control of convulsive
Epilepsy Res. 1998;31:199-209. status epilepticus. Epilepsia. 1998;39:833-840.
41. Gokula RM, Khasnis A. Asterixis. J Postgrad Med. 2003;49:272-275. 63. Jaitly R, Sgro JA, Towne AR, Ko D, DeLorenzo RJ. Prognostic
value of EEG monitoring after status epilepticus: a prospective
42. Kanemoto K, Ozawa K. A case of post-anoxic encephalopathy adult study. J Clin Neurophysiol. 1997;14:326-334.
with initial massive myoclonic status followed by alternating
Jacksonian seizures. Seizure. 2000;9:352-355. 64. Bleck TP. Status epilepticus and the use of continuous elec-
troencephalographic monitoring in the intensive care unit.
43. Van Keulen SG, Burton JH. Myoclonus associated with etomi- Continuum Neurology. 2012;18:560-578.
date for ED procedural sedation and analgesia. Am J Emerg
Med. 2003;21:556-558. 65. Haenggi D; The Participants in the International Multi-
disciplinary Consensus Conference on the Critical Care
44. Jhun P, Kim H. Nonconvulsive status epilepticus in hepatic Management of Subarachnoid Hemorrhage. Monitoring and
encephalopathy. West J Emerg Med. 2012;12:372-374.
detection of vasospasm II: EEG and invasive monitoring.
45. Rocco M, Pro S, Alessandri E, Vicenzini E, Mecarelli O. Neurocritical Care. 2011;15:318-323.
Nonconvulsive status epilepticus induced by acute hypothyroid-
ism in a critically ill patient. Intensive Care Med. 2011;37:553-554. 66. Group FSTGFST. Randomized clinical trial on the efficacy of
antiepileptic drugs in reducing the risk of relapse after a first
46. Campise M. Neurological complication during imipenem/ unprovoked tonic-clonic seizure. Neurology. 1993;43:478-483.
cilastatin therapy in uraemic patients. Nephrol Dial Transplant.
1998;13:1895-1896. 67. Musicco M, Beghi E, Solari A, Viani F. Treatment of first tonic-
clonic seizure does not improve the prognosis of epilepsy.
47. Kushner JM, Peckman HJ, Snyder CR. Seizures associated with First Seizure Trial Group (FIRST Group). Neurology. 1997;49:
fluoroquinolones. Ann Pharmacother. 2001;35:1194-1198. 991-998.
48. Thabet F, Al Maghrabi M, Al Barraq A, Tabarki B. Cefepime- 68. DeToledo JC, Ramsay RE. Fosphenytoin and phenytoin in
induced nonconvulsive status epilepticus: case report and patients with status epilepticus: improved tolerability versus
review. Neurocrit Care. 2009;10:347-351. increased costs. Drug Saf. 2000;22:459-466.
49. Cooling DS. Theophylline toxicity. J Emerg Med. 1993;11:415-425. 69. Knapp LE, Kugler AR. Clinical experience with fosphenytoin
50. Baldini M, Bartolini E, Gori S, et al. Epilepsy after neuro- in adults: pharmacokinetics, safety, and efficacy. J Child Neurol.
imaging normalization in a woman with tacrolimus-related 1998;13(suppl 1):S15-S18; discussion S30-S32.
posterior reversible encephalopathy syndrome. Epilepsy Behav. 70. Smith MC, Bleck TP. Toxicity of anticonvulsants. In: Klawans HL,
2010;17:558-560. Goetz CG, Tanner CM, eds. Textbook of Clinical Neuropharmacology.
51. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neuro- 2nd ed. New York, NY: Raven Press; 1992:45.
toxicity: a review. J Neurol. 1999;246:339-346. 71. Lee CH, Lee CY, Tsai TS, Liou HH. PKA-mediated phosphory-
52. Jaaskelainen SK, Kaisti K, Suni L, Hinkka S, Scheinin H. lation is a novel mechanism for levetiracetam, an antiepilep-
Sevoflurane is epileptogenic in healthy subjects at surgical levels tic drug, activating ROMK1 channels. Biochem Pharmacol.
of anesthesia. Neurology. 2003;61:1073-1078. 2008;76:225-235.
53. Montes FR, Pardo DF, Carreno M, Arciniegas C, Dennis RJ, 72. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward
Umana JP. Risk factors associated with postoperative seizures in ideal characteristics. Pharmacol Ther. 2000;85:77-85.

Section06-O-ref.indd 2 12/10/2014 6:03:39 PM